top of page

Moberg begins patient enrolment in US and Europe Phase 3 onychomycosis trials

Moberg Pharma have begun patient enrolment in the US, Canada and Germany in the Phase 3 program investigating MOB-015 for the treatment of onychomycosis.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page